Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA.

Disel U, Madison R, Abhishek K, Chung JH, Trabucco SE, Matos AO, Frampton GM, Albacker LA, Reddy V, Karadurmus N, Benson A, Webster J, Paydas S, Cabanillas R, Nangia C, Ozturk MA, Millis SZ, Pal SK, Wilky B, Sokol ES, Gay LM, Soman S, Ganesan S, Janeway K, Stephens PJ, Zhu VW, Ou SI, Lovly CM, Gounder M, Schrock AB, Ross JS, Miller VA, Klempner SJ, Ali SM.

Oncologist. 2019 Oct 11. pii: theoncologist.2018-0528. doi: 10.1634/theoncologist.2018-0528. [Epub ahead of print]

PMID:
31604903
2.

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.

Robichaux JP, Elamin YY, Vijayan RSK, Nilsson MB, Hu L, He J, Zhang F, Pisegna M, Poteete A, Sun H, Li S, Chen T, Han H, Negrao MV, Ahnert JR, Diao L, Wang J, Le X, Meric-Bernstam F, Routbort M, Roeck B, Yang Z, Raymond VM, Lanman RB, Frampton GM, Miller VA, Schrock AB, Albacker LA, Wong KK, Cross JB, Heymach JV.

Cancer Cell. 2019 Oct 14;36(4):444-457.e7. doi: 10.1016/j.ccell.2019.09.001. Epub 2019 Oct 3.

PMID:
31588020
3.

A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability-High Cases in 67,000 Patient Samples.

Trabucco SE, Gowen K, Maund SL, Sanford E, Fabrizio DA, Hall MJ, Yakirevich E, Gregg JP, Stephens PJ, Frampton GM, Hegde PS, Miller VA, Ross JS, Hartmaier RJ, Huang SA, Sun JX.

J Mol Diagn. 2019 Aug 22. pii: S1525-1578(19)30358-7. doi: 10.1016/j.jmoldx.2019.06.011. [Epub ahead of print]

4.

PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib.

Bianchi A, Lopez S, Altwerger G, Bellone S, Bonazzoli E, Zammataro L, Manzano A, Manara P, Perrone E, Zeybek B, Han C, Menderes G, Ratner E, Silasi DA, Huang GS, Azodi M, Newberg JY, Pavlick DC, Elvin J, Frampton GM, Schwartz PE, Santin AD.

Gynecol Oncol. 2019 Oct;155(1):144-150. doi: 10.1016/j.ygyno.2019.08.010. Epub 2019 Aug 18.

PMID:
31434613
5.

Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy.

Goodman AM, Sokol ES, Frampton GM, Lippman SM, Kurzrock R.

Cancer Immunol Res. 2019 Oct;7(10):1570-1573. doi: 10.1158/2326-6066.CIR-19-0149. Epub 2019 Aug 12.

PMID:
31405947
6.

The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy.

Knepper TC, Montesion M, Russell JS, Sokol ES, Frampton GM, Miller VA, Albacker LA, McLeod HL, Eroglu Z, Khushalani NI, Sondak VK, Messina JL, Schell MJ, DeCaprio JA, Tsai KY, Brohl AS.

Clin Cancer Res. 2019 Oct 1;25(19):5961-5971. doi: 10.1158/1078-0432.CCR-18-4159. Epub 2019 Aug 9.

PMID:
31399473
7.

Pan-Cancer Analysis of CDK12 Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype.

Sokol ES, Pavlick D, Frampton GM, Ross JS, Miller VA, Ali SM, Lotan TL, Pardoll DM, Chung JH, Antonarakis ES.

Oncologist. 2019 Jul 10. pii: theoncologist.2019-0214. doi: 10.1634/theoncologist.2019-0214. [Epub ahead of print]

PMID:
31292271
8.

Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer.

Chae YK, Viveiros P, Lopes G, Sukhadia B, Sheikh MM, Saravia D, Florou V, Sokol ES, Frampton GM, Chalmers ZR, Ali SM, Ross JS, Chang S, Wang S, Chiec L, Rahbari A, Mohindra N, Villaflor V, Shin SH, Oh M, Anker J, Park LC, Wang V, Chuang J, Park W.

J Thorac Oncol. 2019 Oct;14(10):1807-1817. doi: 10.1016/j.jtho.2019.06.016. Epub 2019 Jun 22.

PMID:
31238177
9.

Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors.

Chung JH, Dewal N, Sokol E, Mathew P, Whitehead R, Millis SZ, Frampton GM, Bratslavsky G, Pal SK, Lee RJ, Necchi A, Gregg JP, Lara P Jr, Antonarakis ES, Miller VA, Ross JS, Ali SM, Agarwal N.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00283. Epub 2019 May 10.

10.

Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.

Parikh AR, He Y, Hong TS, Corcoran RB, Clark JW, Ryan DP, Zou L, Ting DT, Catenacci DV, Chao J, Fakih M, Klempner SJ, Ross JS, Frampton GM, Miller VA, Ali SM, Schrock AB.

Oncologist. 2019 Oct;24(10):1340-1347. doi: 10.1634/theoncologist.2019-0034. Epub 2019 Apr 30.

PMID:
31040255
11.

Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness.

Goodman AM, Kato S, Chattopadhyay R, Okamura R, Saunders IM, Montesion M, Frampton GM, Miller VA, Daniels GA, Kurzrock R.

Cancer Immunol Res. 2019 Jun;7(6):866-873. doi: 10.1158/2326-6066.CIR-18-0716. Epub 2019 Apr 19.

PMID:
31003990
12.

Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database.

Singal G, Miller PG, Agarwala V, Li G, Kaushik G, Backenroth D, Gossai A, Frampton GM, Torres AZ, Lehnert EM, Bourque D, O'Connell C, Bowser B, Caron T, Baydur E, Seidl-Rathkopf K, Ivanov I, Alpha-Cobb G, Guria A, He J, Frank S, Nunnally AC, Bailey M, Jaskiw A, Feuchtbaum D, Nussbaum N, Abernethy AP, Miller VA.

JAMA. 2019 Apr 9;321(14):1391-1399. doi: 10.1001/jama.2019.3241.

13.

PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers.

Yarchoan M, Albacker LA, Hopkins AC, Montesion M, Murugesan K, Vithayathil TT, Zaidi N, Azad NS, Laheru DA, Frampton GM, Jaffee EM.

JCI Insight. 2019 Mar 21;4(6). pii: 126908. doi: 10.1172/jci.insight.126908. eCollection 2019 Mar 21.

14.

Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.

Hanker AB, Garrett JT, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S, Kim PS, Frampton GM, Sanford E, Owens P, Becker J, Groseclose MR, Castellino S, Joensuu H, Huober J, Brase JC, Majjaj S, Brohée S, Venet D, Brown D, Baselga J, Piccart M, Sotiriou C, Arteaga CL.

Clin Cancer Res. 2019 Feb 15;25(4):1434. doi: 10.1158/1078-0432.CCR-18-4267. No abstract available.

PMID:
30770493
15.

APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy.

Boichard A, Pham TV, Yeerna H, Goodman A, Tamayo P, Lippman S, Frampton GM, Tsigelny IF, Kurzrock R.

Oncoimmunology. 2018 Dec 24;8(3):1550341. doi: 10.1080/2162402X.2018.1550341. eCollection 2019.

16.

Tumor mutational burden and response to programmed cell death protein 1 inhibitors in a case series of patients with metastatic desmoplastic melanoma.

Boussemart L, Johnson A, Schrock AB, Pal SK, Frampton GM, Fabrizio D, Chalmers Z, Lotem M, Gibney G, Russell J, Chmielowski B, Ross JS, Stephens PJ, Miller VA, Ali SM.

J Am Acad Dermatol. 2019 Jun;80(6):1780-1782. doi: 10.1016/j.jaad.2018.12.020. Epub 2018 Dec 18. No abstract available.

17.

Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC.

Goldberg ME, Montesion M, Young L, Suh J, Greenbowe J, Kennedy M, Giaccone G, Akerley WL, Dowlati A, Creelan BC, Hicks JK, Hesketh PJ, Kelly KL, Riess JW, Miller VA, Stephens PJ, Frampton GM, Ali S, Gregg JP, Albacker LA.

PLoS One. 2018 Nov 27;13(11):e0208097. doi: 10.1371/journal.pone.0208097. eCollection 2018.

18.

Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer.

Sokol ES, Feng YX, Jin DX, Basudan A, Lee AV, Atkinson JM, Chen J, Stephens PJ, Frampton GM, Gupta PB, Ross JS, Chung JH, Oesterreich S, Ali SM, Hartmaier RJ.

Ann Oncol. 2019 Jan 1;30(1):115-123. doi: 10.1093/annonc/mdy497.

19.

Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumors.

Zhou C, Yuan Z, Ma W, Qi L, Mahavongtrakul A, Li Y, Li H, Gong J, Fan RR, Li J, Molmen M, Clark TA, Pavlick D, Frampton GM, Forcier B, Moore EH, Shelton DK, Cooke M, Ali SM, Miller VA, Gregg JP, Stephens PJ, Li T.

J Hematol Oncol. 2018 Nov 6;11(1):129. doi: 10.1186/s13045-018-0671-8.

20.

Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy.

Kang H, Pettinga D, Schubert AD, Ladenson PW, Ball DW, Chung JH, Schrock AB, Madison R, Frampton GM, Stephens PJ, Ross JS, Miller VA, Ali SM.

Oncologist. 2019 Jun;24(6):791-797. doi: 10.1634/theoncologist.2018-0334. Epub 2018 Oct 29.

PMID:
30373905
21.

Author Correction: Enhancer decommissioning by LSD1 during embryonic stem cell differentiation.

Whyte WA, Bilodeau S, Orlando DA, Hoke HA, Frampton GM, Foster CT, Cowley SM, Young RA.

Nature. 2018 Oct;562(7728):E24. doi: 10.1038/s41586-018-0487-2.

PMID:
30209401
22.

GNAS, GNAQ, and GNA11 alterations in patients with diverse cancers.

Parish AJ, Nguyen V, Goodman AM, Murugesan K, Frampton GM, Kurzrock R.

Cancer. 2018 Oct 15;124(20):4080-4089. doi: 10.1002/cncr.31724. Epub 2018 Sep 11.

23.

Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade.

Galanina N, Goodman AM, Cohen PR, Frampton GM, Kurzrock R.

Cancer Immunol Res. 2018 Oct;6(10):1129-1135. doi: 10.1158/2326-6066.CIR-18-0121. Epub 2018 Sep 7.

24.

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC.

Riess JW, Gandara DR, Frampton GM, Madison R, Peled N, Bufill JA, Dy GK, Ou SI, Stephens PJ, McPherson JD, Lara PN Jr, Burich RA, Ross JS, Miller VA, Ali SM, Mack PC, Schrock AB.

J Thorac Oncol. 2018 Oct;13(10):1560-1568. doi: 10.1016/j.jtho.2018.06.019. Epub 2018 Jul 5.

25.

Analytical Validation of a Hybrid Capture-Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA.

Clark TA, Chung JH, Kennedy M, Hughes JD, Chennagiri N, Lieber DS, Fendler B, Young L, Zhao M, Coyne M, Breese V, Young G, Donahue A, Pavlick D, Tsiros A, Brennan T, Zhong S, Mughal T, Bailey M, He J, Roels S, Frampton GM, Spoerke JM, Gendreau S, Lackner M, Schleifman E, Peters E, Ross JS, Ali SM, Miller VA, Gregg JP, Stephens PJ, Welsh A, Otto GA, Lipson D.

J Mol Diagn. 2018 Sep;20(5):686-702. doi: 10.1016/j.jmoldx.2018.05.004. Epub 2018 Jun 22.

26.

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, Ali SM, Elvin JA, Singal G, Ross JS, Fabrizio D, Szabo PM, Chang H, Sasson A, Srinivasan S, Kirov S, Szustakowski J, Vitazka P, Edwards R, Bufill JA, Sharma N, Ou SI, Peled N, Spigel DR, Rizvi H, Aguilar EJ, Carter BW, Erasmus J, Halpenny DF, Plodkowski AJ, Long NM, Nishino M, Denning WL, Galan-Cobo A, Hamdi H, Hirz T, Tong P, Wang J, Rodriguez-Canales J, Villalobos PA, Parra ER, Kalhor N, Sholl LM, Sauter JL, Jungbluth AA, Mino-Kenudson M, Azimi R, Elamin YY, Zhang J, Leonardi GC, Jiang F, Wong KK, Lee JJ, Papadimitrakopoulou VA, Wistuba II, Miller VA, Frampton GM, Wolchok JD, Shaw AT, Jänne PA, Stephens PJ, Rudin CM, Geese WJ, Albacker LA, Heymach JV.

Cancer Discov. 2018 Jul;8(7):822-835. doi: 10.1158/2159-8290.CD-18-0099. Epub 2018 May 17.

27.

Detection of clonal hematopoiesis of indeterminate potential in clinical sequencing of solid tumor specimens.

Severson EA, Riedlinger GM, Connelly CF, Vergilio JA, Goldfinger M, Ramkissoon S, Frampton GM, Ross JS, Fratella-Calabrese A, Gay L, Ali S, Miller V, Elvin J, Hadigol M, Hirshfield KM, Rodriguez-Rodriguez L, Ganesan S, Khiabanian H.

Blood. 2018 May 31;131(22):2501-2505. doi: 10.1182/blood-2018-03-840629. Epub 2018 Apr 20. No abstract available.

28.

RET fusions in a small subset of advanced colorectal cancers at risk of being neglected.

Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, Morano F, Fuca G, Nikolinakos P, Drilon A, Hechtman JF, Christiansen J, Gowen K, Frampton GM, Gasparini P, Rossini D, Gigliotti C, Kim ST, Prisciandaro M, Hodgson J, Zaniboni A, Chiu VK, Milione M, Patel R, Miller V, Bardelli A, Novara L, Wang L, Pupa SM, Sozzi G, Ross J, Di Bartolomeo M, Bertotti A, Ali S, Trusolino L, Falcone A, de Braud F, Cremolini C.

Ann Oncol. 2018 Jun 1;29(6):1394-1401. doi: 10.1093/annonc/mdy090.

29.

A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal.

Sun JX, He Y, Sanford E, Montesion M, Frampton GM, Vignot S, Soria JC, Ross JS, Miller VA, Stephens PJ, Lipson D, Yelensky R.

PLoS Comput Biol. 2018 Feb 7;14(2):e1005965. doi: 10.1371/journal.pcbi.1005965. eCollection 2018 Feb.

30.

Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer.

Hartmaier RJ, Trabucco SE, Priedigkeit N, Chung JH, Parachoniak CA, Vanden Borre P, Morley S, Rosenzweig M, Gay LM, Goldberg ME, Suh J, Ali SM, Ross J, Leyland-Jones B, Young B, Williams C, Park B, Tsai M, Haley B, Peguero J, Callahan RD, Sachelarie I, Cho J, Atkinson JM, Bahreini A, Nagle AM, Puhalla SL, Watters RJ, Erdogan-Yildirim Z, Cao L, Oesterreich S, Mathew A, Lucas PC, Davidson NE, Brufsky AM, Frampton GM, Stephens PJ, Chmielecki J, Lee AV.

Ann Oncol. 2018 Apr 1;29(4):872-880. doi: 10.1093/annonc/mdy025.

31.

Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets.

Bolen CR, McCord R, Huet S, Frampton GM, Bourgon R, Jardin F, Dartigues P, Punnoose EA, Szafer-Glusman E, Xerri L, Sujobert P, Salles G, Venstrom JM.

Blood Adv. 2017 Sep 27;1(22):1884-1890. doi: 10.1182/bloodadvances.2016000786. eCollection 2017 Oct 10.

32.

BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy.

Johnson DB, Childress MA, Chalmers ZR, Frampton GM, Ali SM, Rubinstein SM, Fabrizio D, Ross JS, Balasubramanian S, Miller VA, Stephens PJ, Sosman JA, Lovly CM.

Pigment Cell Melanoma Res. 2018 May;31(3):432-436. doi: 10.1111/pcmr.12674. Epub 2017 Dec 16.

33.

Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.

Chung JH, Pavlick D, Hartmaier R, Schrock AB, Young L, Forcier B, Ye P, Levin MK, Goldberg M, Burris H, Gay LM, Hoffman AD, Stephens PJ, Frampton GM, Lipson DM, Nguyen DM, Ganesan S, Park BH, Vahdat LT, Leyland-Jones B, Mughal TI, Pusztai L, O'Shaughnessy J, Miller VA, Ross JS, Ali SM.

Ann Oncol. 2017 Nov 1;28(11):2866-2873. doi: 10.1093/annonc/mdx490.

34.

Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures.

Johnson A, Severson E, Gay L, Vergilio JA, Elvin J, Suh J, Daniel S, Covert M, Frampton GM, Hsu S, Lesser GJ, Stogner-Underwood K, Mott RT, Rush SZ, Stanke JJ, Dahiya S, Sun J, Reddy P, Chalmers ZR, Erlich R, Chudnovsky Y, Fabrizio D, Schrock AB, Ali S, Miller V, Stephens PJ, Ross J, Crawford JR, Ramkissoon SH.

Oncologist. 2017 Dec;22(12):1478-1490. doi: 10.1634/theoncologist.2017-0242. Epub 2017 Sep 14.

35.

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.

Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R.

Mol Cancer Ther. 2017 Nov;16(11):2598-2608. doi: 10.1158/1535-7163.MCT-17-0386. Epub 2017 Aug 23.

36.

Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling.

Pal SK, Ali SM, Yakirevich E, Geynisman DM, Karam JA, Elvin JA, Frampton GM, Huang X, Lin DI, Rosenzweig M, Lipson D, Stephens PJ, Ross JS, Miller VA, Agarwal N, Shuch B, Choueiri TK, Chung JH.

Eur Urol. 2018 Jan;73(1):71-78. doi: 10.1016/j.eururo.2017.05.033. Epub 2017 Jun 4.

PMID:
28592388
37.

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.

Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, Schrock A, Campbell B, Shlien A, Chmielecki J, Huang F, He Y, Sun J, Tabori U, Kennedy M, Lieber DS, Roels S, White J, Otto GA, Ross JS, Garraway L, Miller VA, Stephens PJ, Frampton GM.

Genome Med. 2017 Apr 19;9(1):34. doi: 10.1186/s13073-017-0424-2.

38.

HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.

Hanker AB, Garrett JT, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S, Kim PS, Frampton GM, Sanford E, Owens P, Becker J, Groseclose MR, Castellino S, Joensuu H, Huober J, Brase JC, Majjaj S, Brohée S, Venet D, Brown D, Baselga J, Piccart M, Sotiriou C, Arteaga CL.

Clin Cancer Res. 2017 Aug 1;23(15):4323-4334. doi: 10.1158/1078-0432.CCR-16-2287. Epub 2017 Apr 5. Erratum in: Clin Cancer Res. 2019 Feb 15;25(4):1434.

39.

Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.

Schrock AB, Li SD, Frampton GM, Suh J, Braun E, Mehra R, Buck SC, Bufill JA, Peled N, Karim NA, Hsieh KC, Doria M, Knost J, Chen R, Ou SI, Ross JS, Stephens PJ, Fishkin P, Miller VA, Ali SM, Halmos B, Liu JJ.

J Thorac Oncol. 2017 Jun;12(6):932-942. doi: 10.1016/j.jtho.2017.03.005. Epub 2017 Mar 16.

40.

Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration.

Elvin JA, Gay LM, Ort R, Shuluk J, Long J, Shelley L, Lee R, Chalmers ZR, Frampton GM, Ali SM, Schrock AB, Miller VA, Stephens PJ, Ross JS, Frank R.

Oncologist. 2017 Apr;22(4):416-421. doi: 10.1634/theoncologist.2016-0310. Epub 2017 Mar 10.

41.

Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.

Li H, Ma W, Yoneda KY, Moore EH, Zhang Y, Pu LL, Frampton GM, Molmen M, Stephens PJ, Li T.

J Hematol Oncol. 2017 Feb 28;10(1):64. doi: 10.1186/s13045-017-0433-z.

42.

High-Throughput Genomic Profiling of Adult Solid Tumors Reveals Novel Insights into Cancer Pathogenesis.

Hartmaier RJ, Albacker LA, Chmielecki J, Bailey M, He J, Goldberg ME, Ramkissoon S, Suh J, Elvin JA, Chiacchia S, Frampton GM, Ross JS, Miller V, Stephens PJ, Lipson D.

Cancer Res. 2017 May 1;77(9):2464-2475. doi: 10.1158/0008-5472.CAN-16-2479. Epub 2017 Feb 24.

43.

Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra.

Chmielecki J, Bailey M, He J, Elvin J, Vergilio JA, Ramkissoon S, Suh J, Frampton GM, Sun JX, Morley S, Spritz D, Ali S, Gay L, Erlich RL, Ross JS, Buxhaku J, Davies H, Faso V, Germain A, Glanville B, Miller VA, Stephens PJ, Janeway KA, Maris JM, Meshinchi S, Pugh TJ, Shern JF, Lipson D.

Cancer Res. 2017 Jan 15;77(2):509-519. doi: 10.1158/0008-5472.CAN-16-1106. Epub 2017 Jan 9.

44.

Primary Intraosseous Smooth Muscle Tumor of Uncertain Malignant Potential: Original Report and Molecular Characterization.

Kropp L, Siegal GP, Frampton GM, Rodriguez MG, McKee S, Conry RM.

Rare Tumors. 2016 Nov 17;8(4):6507. eCollection 2016 Nov 17.

45.

Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade.

Johnson DB, Frampton GM, Rioth MJ, Yusko E, Xu Y, Guo X, Ennis RC, Fabrizio D, Chalmers ZR, Greenbowe J, Ali SM, Balasubramanian S, Sun JX, He Y, Frederick DT, Puzanov I, Balko JM, Cates JM, Ross JS, Sanders C, Robins H, Shyr Y, Miller VA, Stephens PJ, Sullivan RJ, Sosman JA, Lovly CM.

Cancer Immunol Res. 2016 Nov;4(11):959-967. Epub 2016 Sep 26.

46.

Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias.

Wang K, Sanchez-Martin M, Wang X, Knapp KM, Koche R, Vu L, Nahas MK, He J, Hadler M, Stein EM, Tallman MS, Donahue AL, Frampton GM, Lipson D, Roels S, Stephens PJ, Sanford EM, Brennan T, Otto GA, Yelensky R, Miller VA, Kharas MG, Levine RL, Ferrando A, Armstrong SA, Krivtsov AV.

Leukemia. 2017 Jan;31(1):151-158. doi: 10.1038/leu.2016.166. Epub 2016 Jun 13.

47.

Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.

Schrock AB, Frampton GM, Suh J, Chalmers ZR, Rosenzweig M, Erlich RL, Halmos B, Goldman J, Forde P, Leuenberger K, Peled N, Kalemkerian GP, Ross JS, Stephens PJ, Miller VA, Ali SM, Ou SH.

J Thorac Oncol. 2016 Sep;11(9):1493-502. doi: 10.1016/j.jtho.2016.06.004. Epub 2016 Jun 22.

48.

Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.

Ali SM, Hensing T, Schrock AB, Allen J, Sanford E, Gowen K, Kulkarni A, He J, Suh JH, Lipson D, Elvin JA, Yelensky R, Chalmers Z, Chmielecki J, Peled N, Klempner SJ, Firozvi K, Frampton GM, Molina JR, Menon S, Brahmer JR, MacMahon H, Nowak J, Ou SH, Zauderer M, Ladanyi M, Zakowski M, Fischbach N, Ross JS, Stephens PJ, Miller VA, Wakelee H, Ganesan S, Salgia R.

Oncologist. 2016 Jun;21(6):762-70. doi: 10.1634/theoncologist.2015-0497. Epub 2016 May 31.

49.

Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes.

Chung JH, Sanford E, Johnson A, Klempner SJ, Schrock AB, Palma NA, Erlich RL, Frampton GM, Chalmers ZR, Vergilio J, Rubinson DA, Sun JX, Chmielecki J, Yelensky R, Suh JH, Lipson D, George TJ Jr, Elvin JA, Stephens PJ, Miller VA, Ross JS, Ali SM.

Ann Oncol. 2016 Jul;27(7):1336-41. doi: 10.1093/annonc/mdw152. Epub 2016 Apr 6.

PMID:
27052656
50.

Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting.

He J, Abdel-Wahab O, Nahas MK, Wang K, Rampal RK, Intlekofer AM, Patel J, Krivstov A, Frampton GM, Young LE, Zhong S, Bailey M, White JR, Roels S, Deffenbaugh J, Fichtenholtz A, Brennan T, Rosenzweig M, Pelak K, Knapp KM, Brennan KW, Donahue AL, Young G, Garcia L, Beckstrom ST, Zhao M, White E, Banning V, Buell J, Iwanik K, Ross JS, Morosini D, Younes A, Hanash AM, Paietta E, Roberts K, Mullighan C, Dogan A, Armstrong SA, Mughal T, Vergilio JA, Labrecque E, Erlich R, Vietz C, Yelensky R, Stephens PJ, Miller VA, van den Brink MR, Otto GA, Lipson D, Levine RL.

Blood. 2016 Jun 16;127(24):3004-14. doi: 10.1182/blood-2015-08-664649. Epub 2016 Mar 10.

Supplemental Content

Loading ...
Support Center